Effect of combined T- and B-cell depletion of allogeneic HLA-mismatched bone marrow graft on the magnitude and kinetics of Epstein–Barr virus load in the peripheral blood of bone marrow transplant recipients
Daorong Liu, Charlotte Tammik,
Jie-Zhi Zou, Ingemar Ernberg, Maria G. Masucci, Olle Ringden,
Victor Levitsky,
Charlotte Tammik
Department of Clinical Immunology and Center for Allogeneic Stem Cell Transplantation at Huddinge Hospital, Karolinska Institutet, Stockholm, Sweden
Search for more papers by this authorOlle Ringden
Department of Clinical Immunology and Center for Allogeneic Stem Cell Transplantation at Huddinge Hospital, Karolinska Institutet, Stockholm, Sweden
Search for more papers by this authorDaorong Liu, Charlotte Tammik,
Jie-Zhi Zou, Ingemar Ernberg, Maria G. Masucci, Olle Ringden,
Victor Levitsky,
Charlotte Tammik
Department of Clinical Immunology and Center for Allogeneic Stem Cell Transplantation at Huddinge Hospital, Karolinska Institutet, Stockholm, Sweden
Search for more papers by this authorOlle Ringden
Department of Clinical Immunology and Center for Allogeneic Stem Cell Transplantation at Huddinge Hospital, Karolinska Institutet, Stockholm, Sweden
Search for more papers by this authorV. Levitsky, Microbiology and Tumor Biology Center, Karolinska Institutet, Nobels väg 16, S-17177 Stockholm, Sweden.
Tel.: 46-8-7286290; fax: 46-8-331399;
e-mail: [email protected]
Abstract
Abstract: Recipients of T-cell-depleted bone marrow (BM) transplants (BMT) frequently develop Epstein–Barr virus (EBV)-associated post-transplant lymphoproliferative disease (PTLD) preceded by a rapid and prominent increase of EBV load in the peripheral blood. The level of this increase positively correlates with the incidence of PTLD. Using a semiquantitative PCR assay we compared the blood levels of EBV-DNA in patients transplanted with either T-cell or T- and B-cell-depleted human leukocyte antigen (HLA)-mismatched BM grafts. Combined T- and B-cell depletion correlated with significantly lower maximal levels of EBV load, which were reached with slower kinetics. These data indicate that B-cell depletion of BM can be used for prophylaxis of PTLD in BM transplant recipients and can affect the long-term balance between EBV and its host.
References
- 1 Rickinson AB, Kieff E. Epstein-Barr virus. In: BN Fields, DM Knipe, PM Howley eds. Fields Virology. Philadelphia, PA: Lippincott-Raven Publishers, 1996: 2397.
- 2 Hanto DW, Sakamoto K, Purtilo DT, Simmons RL, Najarian JS. The Epstein-Barr virus in the pathogenesis of posttransplant lymphoproliferative disorders. Clinical, pathologic, and virologic correlation. Surgery 1981: 90: 204.
- 3 Hanto DW, Gajl-Peczalska KJ, Frizzera G et al. Epstein-Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation. Clinical, pathologic, and virologic findings and implications for therapy. Ann Surg 1983: 198: 356.
- 4 Orazi A, Hromas RA, Neiman RS et al. Posttransplantation lymphoproliferative disorders in bone marrow transplant recipients are aggressive diseases with a high incidence of adverse histologic and immunobiologic features. Am J Clin Pathol 1997: 107: 419.
- 5 Nalesnik MA, Jaffe R, Starzl TE et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisolone immunosuppression. Am J Pathol 1988: 133: 173.
- 6 Shapiro RS, McClain K, Frizzera G et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988: 71: 1234.
- 7 Gustafsson A, Levitsky V, Zou J-Z et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000: 95: 807.
- 8 Green M, Cacciarelli TV, Mazariegos GV et al. Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease. Transplantation 1998: 66: 1641.
- 9 Kenagy DN, Schlesinger Y, Weck K, Ritter JH, Gaudreault-Keener MM, Storch GA. Epstein-Barr virus DNA in peripheral blood leukocytes of patients with posttransplant lymphoproliferative disease. Transplantation 1995: 60: 547.
- 10 Riddler SA, Breinig MC, McKnight JL. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood 1994: 84: 972.
- 11 Rooney CM, Loftin SK, Holladay MS, Brenner MK, Krance RA, Heslop HE. Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol 1995: 89: 98.
- 12 Savoie A, Perpete C, Carpentier L, Joncas J, Alfieri C. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood 1994: 83: 2715.
- 13 Stevens SJ, Verschuuren EA, Pronk I et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001: 97: 1165.
- 14 Babcock GJ, Decker LL, Volk M, Thorley-Lawson DA. EBV persistence in memory B cells in vivo. Immunity 1998: 9: 395.
- 15 Babcock GJ, Decker LL, Freeman RB, Thorley-Lawson DA. Epstein-Barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J Exp Med 1999: 190: 567.
- 16 Yang J, Tao Q, Flinn IW et al. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood 2000: 96: 4055.
- 17 Campe H, Jaeger G, Abou-Ajram C et al. Serial detection of Epstein-Barr virus DNA in sera and peripheral blood leukocyte samples of pediatric renal allograft recipients with persistent mononucleosis-like symptoms defines patients at risk to develop post-transplant lymphoproliferative disease. Pediatr Transplant 2003: 7: 46.
- 18 Babcock GJ, Hochberg D, Thorley-Lawson AD. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 2000: 13: 497.
- 19 Aguilar LK, Rooney CM, Heslop HE. Lymphoproliferative disorders involving Epstein-Barr virus after hemopoietic stem cell transplantation. Curr Opin Oncol 1999: 11: 96.
- 20 Cavazzana-Calvo M, Bensoussan D, Jabado N et al. Prevention of EBV-induced B-lymphoproliferative disorder by ex vivo marrow B-cell depletion in HLA-phenoidentical or non-identical T-depleted bone marrow transplantation. Br J Haematol 1998: 103: 543.
- 21 Hale G, Waldmann H. Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users. Blood 1998: 91: 3079.
- 22 Olerup O, Zetterquist H. HLA-DR typic by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992: 39: 225.
- 23 Oakhill A, Pamphilon DH, Potter MN et al. Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukaemia in second complete remission. Br J Haematol 1996: 94: 574.
- 24 Ringden O, Båryd I, Johansson B et al. Increased mortality by septicemia, interstitial pneumonitis and pulmonary fibrosis among bone marrow transplant recipients receiving an increased mean dose rate of total irradiation. Acta Radiol Oncol 1983: 22: 423.
- 25 Ringden O, Remberger M, Carlens S et al. Low incidence of acute graft-versus-host disease, using unrelated HLA-A-, HLA-B-, and HLA-DR-compatible donors and conditioning, including anti-T-cell antibodies. Transplantation 1998: 66: 620.
- 26 Remberger M, Svahn BM, Hentschke P, Lofgren C, Ringden O. Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplant 1999: 24: 823.
- 27 Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986: 314: 729.
- 28 Ringden O, Remberger M, Persson U et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 1995: 15: 619.
- 29 Chen F, Zou J-Z, di Renzo L et al. A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1. J Virol 1995: 69: 3752.
- 30 Holmes RD, Sokol RJ. Epstein-Barr virus and post-transplant lymphoproliferative disease. Pediatr Transplant 2002: 6: 456.
- 31 Loren AW, Porter DL, Stadtmauer EA, Tsai DE. Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant 2003: 31: 145.
- 32 Verschuuren EA, Stevens SJ, van Imhoff GW et al. Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication. Transplantation 2002: 73: 100.
- 33 Rooney CM, Smith CA, Ng CYC et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus -induced lymphoma in allogeneic transplant recipients. Blood 1998: 92: 1549.
- 34 Rooney CM, Smith CA, Ng CYC et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. The Lancet 1995: 345: 9.
- 35 Heslop HE, Ng CYC, Li C et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nature Med 1996: 2: 551.
- 36 Gottschalk S, Ng CY, Perez M et al. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood 2001: 97: 835.
- 37 Chakrabarti S, MacDonald D, Hale G et al. T-cell depletion with Campath-1H ‘‘in the bag’’ for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival. Br J Haematol 2003: 121: 109.
- 38 Chakrabarti S, Milligan DW, Pillay D et al. Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation. Blood 2003: 102: 839.
- 39 Savard M, Bélanger C, Tardif M, Gourde P, Flamand L, Gosselin J. Infection of primary human monocytes by Epstein-Barr virus. J Immunol 2000: 74: 2612.
- 40 Imai S, Nishikawa J, Takada K. Cell-to-cell contact as an efficient mode of Epstein-Barr virus infection of diverse human epithelial cells. J Virol 1998: 72: 4371.
- 41 Larochelle B, Flamand L, Gourde P, Beauchamp D, Gosselin J. Epstein-Barr virus infects and induces apoptosis in human neutrophils. Blood 1998: 92: 291.
- 42 Alexander FE, Jarrett RF, Lawrence D et al. Risk factors for Hodgkin's disease by Epstein-Barr virus (EBV) status: prior infection by EBV and other agents. Br J Cancer 2000: 82: 1117.
- 43 Mueller N. Epidemiologic studies assessing the role of the Epstein-Barr virus in Hodgkin's disease. Yale J Biol Med 1987: 60: 321.
